Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE: AZD9977 plus dapagliflozin in heart failure with chronic kidney disease
jRCT2031200272Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of balcinrenone and dapagliflozin in heart failure (HF) and chronic kidney disease (CKD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Percent change from baseline in UACR at 12 weeks. Started Jun 2021; status: completed.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031200272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200272.